Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)
393.44
-3.30 (-0.83%)
NASDAQ · Last Trade: Nov 20th, 10:20 AM EST
Kaplan Fox Alerts Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to an Ongoing Investigation Into Possible Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 19, 2026
Kaplan Fox Encourages Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to Contact the Firm Regarding an Ongoing Securities Investigation
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 19, 2026
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Possible Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 18, 2026
Kaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
By Kaplan Fox & Kilsheimer, LLP · Via GlobeNewswire · November 18, 2026
Kaplan Fox Announces an Investigation Into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Possible Securities Law Violations
NEW YORK, NY - November 17, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
Via NewMediaWire · November 17, 2026
Kaplan Fox Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 16, 2026
Kaplan Fox Reminds Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding an Investigation of Potential Securities Law Violations
NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
By Kaplan Fox & Kilsheimer, LLP · Via GlobeNewswire · November 16, 2026
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations - Investors Encouraged to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 13, 2026
Kaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations
NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
By Kaplan Fox & Kilsheimer, LLP · Via GlobeNewswire · November 13, 2026
Kaplan Fox Reminds Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) of an Ongoing Investigation Into Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 12, 2026
Kaplan Fox Announces an Investigation of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) on Behalf of Investors
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 12, 2026
Kaplan Fox is Investigating Potential Securities Law Violations Against Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 11, 2026
Kaplan Fox Encourages Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to Contact the Firm Regarding an Investigation of Possible Securities Law Violations
NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
By Kaplan Fox & Kilsheimer, LLP · Via GlobeNewswire · November 11, 2026
MADRIGAL PHARMACEUTICALS, INC. MDGL INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 8.1% Share Drop
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
By Kirby McInerney LLP · Via Business Wire · November 11, 2026
Kaplan Fox Notifies Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) of an Investigation Into Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 10, 2026
NASDAQ: MDGL Investigation: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, PA - November 10, 2026 (NEWMEDIAWIRE) - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Madrigal Pharmaceuticals, Inc. (“Madrigal”) (NASDAQ: MDGL) on behalf of investors who purchased or acquired Madrigal securities and experienced significant financial losses.
Via NewMediaWire · November 10, 2026
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations Investors are Encouraged to Contact the Firm
NEW YORK, NY - November 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
Via NewMediaWire · November 10, 2026
Kaplan Fox Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 9, 2026
Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law Violations
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL).
By Kaplan Fox & Kilsheimer, LLP · Via GlobeNewswire · November 9, 2026
Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 9, 2026
Madrigal Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Madrigal Pharmaceuticals (MDGL)
NEW YORK CITY, NY / ACCESS Newswire / November 9, 2026 / Madrigal Pharmaceuticals (NASDAQ:MDGL) shareholders lost $34.84 per share on November 3, 2026, when the stock fell 8.1% after the Company disclosed a whistleblower complaint filed by its former Senior Vice President, Head of Clinical Development. If you suffered a loss on your Madrigal investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
By Levi & Korsinsky, LLP · Via ACCESS Newswire · November 9, 2026
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Madrigal Pharmaceuticals, Inc. (“Madrigal” or “the Company”) (NASDAQ: MDGL) for violations of the securities laws.
By Schall, Brown & Schwartz LLP · Via Business Wire · November 8, 2026
Kaplan Fox Announces an Investigation Into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 6, 2026
NASDAQ: MDGL INVESTIGATION ALERT: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Madrigal Pharmaceuticals, Inc. (“Madrigal”) (NASDAQ: MDGL) on behalf of investors who purchased or acquired Madrigal securities and experienced significant financial losses.
By Kessler Topaz Meltzer & Check, LLP · Via Business Wire · November 6, 2026
Lost Money on Madrigal Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 8.1% Share Price Drop
Investors who lost money on Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 3, 2026 disclosure regarding Madrigal Pharmaceuticals, Inc.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · November 6, 2026